Fentanyl and Stimulant Overdoses Surge 9000% in Seniors

Fatal overdoses among adults aged 65 and older that involve fentanyl combined with stimulants such as cocaine and methamphetamines have increased dramatically over the past eight years, rising by an astonishing 9,000 percent. The current rate among this older population now closely matches the rates

Fatal overdoses among adults aged 65 and older that involve fentanyl combined with stimulants such as cocaine and methamphetamines have increased dramatically over the past eight years, rising by an astonishing 9,000 percent. The current rate among this older population now closely matches the rates observed in younger adults, based on research presented at the ANESTHESIOLOGY 2025 annual meeting.

This investigation stands out as one of the earliest efforts to leverage data from the Centers for Disease Control and Prevention to demonstrate that older adults, frequently overlooked in overdose statistics, are becoming increasingly involved in the nationwide increase of fentanyl-stimulant fatalities. Individuals within this demographic encounter elevated overdose risks due to the management of ongoing health conditions, the use of multiple medications simultaneously, and slower drug metabolism associated with aging processes.

Specialists characterize the opioid epidemic as progressing through four separate phases, each linked to a distinct substance responsible for fatal overdoses. These phases include prescription opioids during the 1990s, heroin around 2010, fentanyl gaining prominence in 2013, and the combination of fentanyl with stimulants starting in 2015.

A widespread belief holds that opioid overdoses mainly impact younger individuals, noted Gab Pasia, the study's lead author and a medical student at the University of Nevada, Reno School of Medicine. The analysis reveals that older adults are also experiencing significant effects from fentanyl-related fatalities and that stimulant involvement has grown substantially more prevalent within this demographic. Such patterns indicate that older adults are being influenced by the ongoing fourth wave of the opioid crisis, mirroring trends previously observed in younger groups.

To carry out the investigation, the team reviewed 404,964 death certificates that identified fentanyl as a contributing factor from 1999 through 2023, drawing from the CDC Wide-ranging Online Data for Epidemiologic Research system. Among these fatalities, 17,040 occurred in adults 65 and older, whereas 387,924 took place in adults between the ages of 25 and 64.

From 2015 to 2023, fatalities connected to fentanyl climbed from 264 to 4,144 among older adults, representing a 1,470 percent increase, and from 8,513 to 64,694 among younger adults, marking a 660 percent rise. In the older group, deaths involving both fentanyl and stimulants expanded from 8.7 percent, or 23 out of 264 fentanyl deaths, in 2015 to 49.9 percent, or 2,070 out of 4,144, in 2023, amounting to a remarkable 9,000 percent growth. By contrast, among younger adults, fentanyl-stimulant deaths increased from 21.3 percent, or 1,812 out of 8,513, to 59.3 percent, or 38,333 out of 64,694, during the identical timeframe, reflecting a 2,115 percent rise.

The researchers selected 2015 and 2023 for emphasis in their examination because 2015 signaled the start of the epidemic's fourth wave, when fentanyl-stimulant deaths among older adults reached their lowest point, and 2023 provided the latest available CDC data at the time of analysis.

The team observed that the increase in fentanyl deaths involving stimulants among older adults began accelerating sharply in 2020, whereas deaths associated with other substances remained steady or decreased. Cocaine and methamphetamines emerged as the primary stimulants combined with fentanyl in the older adults examined, outpacing alcohol, heroin, and benzodiazepines including Xanax and Valium.

National statistics have indicated growing fentanyl-stimulant consumption across all adult populations, explained Mr. Pasia. Since the analysis represented a national cross-sectional study, it could only outline temporal patterns rather than identify the root causes behind these developments. Nevertheless, the results emphasize that fentanyl overdoses in older adults frequently involve multiple substances rather than fentanyl in isolation and highlight the necessity of extending drug misuse prevention approaches to older patients.

The authors pointed out that anesthesiologists and other pain medicine experts should recognize that polysubstance use may affect every age group and not solely younger adults. They should exercise caution when prescribing opioids to adults 65 or older by thoroughly evaluating medication histories, maintaining close supervision of patients prescribed opioids who might have a background of stimulant use to watch for potential adverse effects, and exploring non-opioid alternatives whenever feasible. Additionally, they should apply harm-reduction strategies such as engaging caregivers in naloxone education, streamlining medication schedules, employing clear labeling along with safe storage guidance, and ensuring instructions remain accessible for individuals facing memory or vision difficulties. Finally, they should screen older patients for a wide spectrum of substance exposures beyond prescribed opioids to better foresee complications and refine perioperative planning.

Older adults prescribed opioids, or their caregivers, ought to inquire with their healthcare providers about overdose prevention measures, including maintaining access to naloxone and recognizing overdose indicators, stated Richard Wang, an anesthesiology resident at Rush University Medical Center in Chicago and co-author of the study. Given these patterns, it has become more critical than ever to reduce opioid utilization within this at-risk population and to employ alternative pain management techniques when suitable. Thorough patient education combined with routine reviews of medication lists may assist in reversing this concerning development.